typhim vi- salmonella typhi ty2 vi polysaccharide antigen injection, solution
a-s medication solutions - salmonella typhi ty2 vi polysaccharide antigen (unii: 7194h8w3kt) (salmonella typhi ty2 vi polysaccharide antigen - unii:7194h8w3kt) - salmonella typhi ty2 vi polysaccharide antigen 25 ug in 0.5 ml - typhim vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by s typhi and is approved for use in persons two years of age or older. immunization with typhim vi vaccine should occur at least two weeks prior to expected exposure to s typhi . typhim vi vaccine is not indicated for routine immunization of individuals in the united states (us). (14) selective immunization against typhoid fever is recommended under the following circumstances: 1) travelers to areas where a recognized risk of exposure to typhoid exists, particularly ones who will have prolonged exposure to potentially contaminated food and water, 2) persons with intimate exposure (ie, continued household contact) to a documented typhoid carrier, and 3) workers in microbiology laboratories who frequently work with s typhi . (14) typhoid vaccination is not required for international travel, but is recommended for travelers to such areas as africa, asia, and central and south america where there is a recognized r
typhim vi- salmonella typhi ty2 vi polysaccharide antigen injection, solution
a-s medication solutions - salmonella typhi ty2 vi polysaccharide antigen (unii: 7194h8w3kt) (salmonella typhi ty2 vi polysaccharide antigen - unii:7194h8w3kt) - salmonella typhi ty2 vi polysaccharide antigen 25 ug in 0.5 ml - typhim vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by s typhi and is approved for use in persons two years of age or older. immunization with typhim vi vaccine should occur at least two weeks prior to expected exposure to s typhi . typhim vi vaccine is not indicated for routine immunization of individuals in the united states (us). (14) selective immunization against typhoid fever is recommended under the following circumstances: 1) travelers to areas where a recognized risk of exposure to typhoid exists, particularly ones who will have prolonged exposure to potentially contaminated food and water, 2) persons with intimate exposure (ie, continued household contact) to a documented typhoid carrier, and 3) workers in microbiology laboratories who frequently work with s typhi . (14) typhoid vaccination is not required for international travel, but is recommended for travelers to such areas as africa, asia, and central and south america where there is a recognized r
prevenar 13 suspension for injection
pfizer manufacturing belgium n.v. - pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f) - suspension for injection - 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 4.4mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose
pneumovax 23 (prefilled syringe)
msd pharma (singapore) pte. ltd. - pneumococcal polysaccharides 23 most prevalent types - injection - pneumococcal polysaccharides 23 most prevalent types 25mcg/0.5ml of each type
prevenar 13 suspension for injection
wyeth pharmaceuticals - pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal pol - suspension for injection - 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 4.4mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1
prevenar 13 suspension for injection
pfizer manufacturing belgium nv - pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal pol - suspension for injection - 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 4.4mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose
pneumovax 23 inj. sol. s.c./i.m. vial
msd belgium bv-srl - streptococcus pneumoniae type 7f purified capsular polysaccharides ; streptococcus pneumoniae type 9v purified capsular polysaccharides ; streptococcus pneumoniae type 11a purified capsular polysaccharides ; streptococcus pneumoniae type 14 purified capsular polysaccharides ; streptococcus pneumoniae type 18c purified capsular polysaccharides ; streptococcus pneumoniae type 12f purified capsular polysaccharides ; streptococcus pneumoniae type 22f purified capsular polysaccharides ; streptococcus pneumoniae type 10a purified capsular polysaccharides ; streptococcus pneumoniae type 33f purified capsular polysaccharides ; streptococcus pneumoniae type 5 purified capsular polysaccharides ; streptococcus pneumoniae type 23f purified capsular polysaccharides ; streptococcus pneumoniae type 8 purified capsular polysaccharides ; streptococcus pneumoniae type 20 purified capsular polysaccharides ; streptococcus pneumoniae type 4 purified capsular polysaccharides ; streptococcus pneumoniae type 19f purified capsular polysaccharides ; streptococcus pneumoniae type 6b purified capsular polysaccharides ; streptococcus pneumoniae type 17f purified capsular polysaccharides ; streptococcus pneumoniae type 2 purified capsular polysaccharides ; streptococcus pneumoniae type 19a purified capsular polysaccharides ; streptococcus pneumoniae type 9n purified capsular polysaccharides ; streptococcus pneumoniae type 15b purified capsular polysaccharides ; streptococcus pneumoniae type 3 purified capsular polysaccharides ; streptococcus pneumoniae type 1 purified capsular polysaccharides - solution for injection - pneumococcal polysaccharide vaccine, 23-valent - pneumococcus, purified polysaccharides antigen
prevenar 13 suspension for injection
pfizer manufacturing belgium nv - pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f) - suspension for injection - 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 4.4mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose
pneumo 23 vaccine
sanofi-aventis singapore pte. ltd. - polysaccharides of streptococcus pneumoniae (purified) - injection - 25ug for each of the 23 serotypes
pneumovax 23
merck sharp & dohme australia pty ltd - pneumococcal purified capsular polysaccharides -